Salarius Pharmaceuticals' stock was trading at $0.7201 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SLRX stock has decreased by 50.4% and is now trading at $0.3571. View which stocks have been most impacted by COVID-19.
Full Answer
Are salarius pharmaceuticals insiders buying or selling stock?
In the past three months, Salarius Pharmaceuticals insiders have not sold or bought any company stock. Only 0.66% of the stock of Salarius Pharmaceuticals is held by insiders. Only 22.60% of the stock of Salarius Pharmaceuticals is held by institutions.
What is the upside for salarius pharmaceuticals (SLRX) stock?
Their forecasts range from $5.00 to $5.00. On average, they expect Salarius Pharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 908.9% from the stock's current price. View analysts' price targets for Salarius Pharmaceuticals or view top-rated stocks among Wall Street analysts.
What is salarius Therapeutics Inc (salr)?
The firm focuses on the development of Salarius’ clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.
What was the gross proceeds from the purchase of 9339 shares?
The firm entered into definitive agreements with several institutional investors for the purchase of 9,339,436 shares of its common stock at $0.25/share. Gross proceeds is estimated to be ~$2.3M.
What happened to Salarius pharmaceuticals?
(Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that Salarius Pharmaceuticals, LLC, has closed its merger with Flex Pharma, Inc.'s wholly owned subsidiary on July 19, 2019. Flex Pharma, Inc. has been renamed and will operate as Salarius Pharmaceuticals, Inc.
Is Salarius Pharmaceuticals a good stock to buy?
Salarius Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Is SLRX a good investment?
Salarius Pharmaceuticals Inc (NASDAQ:SLRX) The 1 analysts offering 12-month price forecasts for Salarius Pharmaceuticals Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a +2,560.99% increase from the last price of 0.19.
Should I buy or sell Salarius Pharmaceuticals stock right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Salarius Pharmaceuticals in the last year. There are currently 1 buy ratin...
What is Salarius Pharmaceuticals' stock price forecast for 2022?
1 brokerages have issued 12-month price objectives for Salarius Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, the...
How has Salarius Pharmaceuticals' stock price performed in 2022?
Salarius Pharmaceuticals' stock was trading at $0.4956 at the beginning of the year. Since then, SLRX shares have decreased by 58.4% and is now tra...
When is Salarius Pharmaceuticals' next earnings date?
Salarius Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast...
How were Salarius Pharmaceuticals' earnings last quarter?
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) released its earnings results on Thursday, November, 4th. The company reported ($0.08) earnings per sh...
Who are Salarius Pharmaceuticals' key executives?
Salarius Pharmaceuticals' management team includes the following people: Mr. David J. Arthur M.B.A. , CEO, Pres & Director (Age 59, Pay $676.75k...
Who are some of Salarius Pharmaceuticals' key competitors?
Some companies that are related to Salarius Pharmaceuticals include Larimar Therapeutics (LRMR) , Connect Biopharma (CNTB) , NexImmune (NEXI) ,...
What other stocks do shareholders of Salarius Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Evofem Bios...
What is Salarius Pharmaceuticals' stock symbol?
Salarius Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLRX."
Is Salarius Pharmaceuticals stock a Buy, Sell or Hold?
Salarius Pharmaceuticals stock has received a consensus rating of buy. The average rating score is and is based on 3 buy ratings, 0 hold ratings, a...
What was the 52-week low for Salarius Pharmaceuticals stock?
The low in the last 52 weeks of Salarius Pharmaceuticals stock was 0.16. According to the current price, Salarius Pharmaceuticals is 115.56% away f...
What was the 52-week high for Salarius Pharmaceuticals stock?
The high in the last 52 weeks of Salarius Pharmaceuticals stock was 1.49. According to the current price, Salarius Pharmaceuticals is 12.41% away f...
What are analysts forecasts for Salarius Pharmaceuticals stock?
The 3 analysts offering price forecasts for Salarius Pharmaceuticals have a median target of 4.67, with a high estimate of 5.00 and a low estimate...
3.5 Analyst's Opinion
Salarius Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Is Salarius Pharmaceuticals a buy right now?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Salarius Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock.
How has Salarius Pharmaceuticals' stock been impacted by COVID-19?
Salarius Pharmaceuticals' stock was trading at $0.7201 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SLRX stock has decreased by 45.1% and is now trading at $0.3955. View which stocks have been most impacted by COVID-19.
When is Salarius Pharmaceuticals' next earnings date?
Salarius Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022. View our earnings forecast for Salarius Pharmaceuticals.
How were Salarius Pharmaceuticals' earnings last quarter?
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) posted its earnings results on Thursday, November, 4th. The company reported ($0.08) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.01.
What price target have analysts set for SLRX?
1 equities research analysts have issued 1-year price objectives for Salarius Pharmaceuticals' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Salarius Pharmaceuticals' stock price to reach $5.00 in the next year.
Who are some of Salarius Pharmaceuticals' key competitors?
Some companies that are related to Salarius Pharmaceuticals include ABVC BioPharma (ABVC), iBio (IBIO), Emmaus Life Sciences (EMMA), vTv Therapeutics (VTVT), Novan (NOVN), Heat Biologics (HTBX), Larimar Therapeutics (LRMR), LifeVantage (LFVN), Akari Therapeutics (AKTX), F-star Therapeutics (FSTX), Gemini Therapeutics (GMTX), Millendo Therapeutics (MLND), Longboard Pharmaceuticals (LBPH), Iterum Therapeutics (ITRM) and Atreca (BCEL). View all of SLRX's competitors..
Salarius expands oncology drug pipeline with DeuteRx portfolio acquisition
The deal "provides entry into the exciting field of protein degradation, a fast-growing area of cancer drug research that is attracting substantial interest from some of the world’s largest pharmaceutical companies because of the potential advantages of protein degraders, including the ability to go after previously undruggable cancer-promoting targets," said David Arthur, CEO of Salarius..
Will Salarius (SLRX) Report Negative Earnings Next Week? What You Should Know
Salarius (SLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why We're Not Too Worried About Salarius Pharmaceuticals' (NASDAQ:SLRX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
When Might Salarius Pharmaceuticals Run Out Of Money?
A company's cash runway is calculated by dividing its cash hoard by its cash burn. In June 2021, Salarius Pharmaceuticals had US$33m in cash, and was debt-free. Looking at the last year, the company burnt through US$10m. Therefore, from June 2021 it had 3.3 years of cash runway.
How Well Is Salarius Pharmaceuticals Growing?
We reckon the fact that Salarius Pharmaceuticals managed to shrink its cash burn by 30% over the last year is rather encouraging. Revenue also improved during the period, increasing by 9.5%. On balance, we'd say the company is improving over time. Clearly, however, the crucial factor is whether the company will grow its business going forward.
Can Salarius Pharmaceuticals Raise More Cash Easily?
We are certainly impressed with the progress Salarius Pharmaceuticals has made over the last year, but it is also worth considering how costly it would be if it wanted to raise more cash to fund faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business.
